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Abstract
Background: Smoking and obesity are risk factors causing a large burden of disease. To help formulate
and prioritize among smoking and obesity prevention activities, estimations of health-adjusted life
expectancy (HALE) for cohorts that differ solely in their lifestyle (e.g. smoking vs. non smoking) can
provide valuable information. Furthermore, in combination with estimates of life expectancy (LE), it can
be tested whether prevention of obesity and smoking results in compression of morbidity.
Methods: Using a dynamic population model that calculates the incidence of chronic disease conditional
on epidemiological risk factors, we estimated LE and HALE at age 20 for a cohort of smokers with a normal
weight (BMI < 25), a cohort of non-smoking obese people (BMI>30) and a cohort of 'healthy living' people
(i.e. non smoking with a BMI < 25). Health state valuations for the different cohorts were calculated using
the estimated disease prevalence rates in combination with data from the Dutch Burden of Disease study.
Health state valuations are multiplied with life years to estimate HALE. Absolute compression of morbidity
is defined as a reduction in unhealthy life expectancy (LE-HALE) and relative compression as a reduction
in the proportion of life lived in good health (LE-HALE)/LE.
Results: Estimates of HALE are highest for a 'healthy living' cohort (54.8 years for men and 55.4 years for
women at age 20). Differences in HALE compared to 'healthy living' men at age 20 are 7.8 and 4.6 for
respectively smoking and obese men. Differences in HALE compared to 'healthy living' women at age 20
are 6.0 and 4.5 for respectively smoking and obese women. Unhealthy life expectancy is about equal for
all cohorts, meaning that successful prevention would not result in absolute compression of morbidity.
Sensitivity analyses demonstrate that although estimates of LE and HALE are sensitive to changes in disease
epidemiology, differences in LE and HALE between the different cohorts are fairly robust. In most cases,
elimination of smoking or obesity does not result in absolute compression of morbidity but slightly
increases the part of life lived in good health.
Conclusion: Differences in HALE between smoking, obese and 'healthy living' cohorts are substantial and
similar to differences in LE. However, our results do not indicate that substantial compression of morbidity
is to be expected as a result of successful smoking or obesity prevention.
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Background
Obesity and smoking are risk factors for major chronic
diseases that influence both length and quality of life [1].
Differences in life expectancy (LE) between smokers and
never smokers have been found ranging from 7.5 years [2]
to 10 years [3]. In a recent study, it was found that obesity
led to decreases of roughly 6 to 7 years in life expectancy
[4]. However, differences in LE alone are not sufficient to
inform on the impact of unhealthy lifestyle since they do
not address the impact on quality of life through disabili-
ties caused by chronic diseases. To address this, summary
measures of population health are needed that combine
information on both length and quality of life [5]. One
such summary measure of population health is health-
adjusted life expectancy (HALE). HALE has been intro-
duced within the Health Expectancy Network (Réseau
Espérance de Vie en Santé, or REVES) and is a summary
measure of population health indicating the expectation
of equivalent years lived in good health [6]. HALE, like LE,
is independent of the size and composition of the popu-
lation and is therefore useful to make comparisons
between populations and over time [5].
A possible application of HALE is to compare cohorts that
differ solely in their lifestyle e.g. smoking versus non
smoking. Although much work has been done to quantify
the current burden of disease attributable to risk factors
[1,7-9] HALE estimations conditional on risk factors have
not yet been published to our knowledge. Combining LE
and HALE estimates conditional on risk factors provides
information on whether prevention of obesity and/or
smoking would result in compression or expansion of
morbidity [2,10], i.e. a decrease or an increase of the
period lived with disability. In a previous study Nusselder
et al. [11] found that eliminating smoking not only
extends life but also results in an increase in the number
of years lived without disability and thus in compression
of morbidity. However, in that study disability was treated
as a dichotomous variable (disability or not). Using disa-
bility weights attached to disease prevalence rates, differ-
ent levels of disability caused by different diseases can be
aggregated into HALE.
The aims of this study are two-fold:
- present HALE estimates for different cohorts defined
conditional on risk factors;
- test whether prevention of obesity and/or smoking
results in compression of morbidity.
Using a dynamic population model that calculates the
incidence of chronic diseases conditional on epidemio-
logical risk factors, we estimated HALE at age 20 for a
cohort of smokers, a cohort of obese people (BMI>30)
and a cohort of 'healthy living' people (i.e. non smoking
with a BMI < 25). First, it is explained how we estimated
HALE using a dynamic population model that combines
input from several data sources. Thereafter, results of LE
and HALE estimates for the different cohorts are pre-
sented. Using the differences between LE and HALE esti-
mates for the different cohorts we will test whether
prevention of obesity and smoking results in compression
of morbidity. In the last section, implications of our
results and methodological issues are discussed.
Methods
Basic framework for estimating LE and HALE
To estimate life expectancy (LE) and HALE, the RIVM
Chronic Disease Model (CDM) was used [12]. The CDM
is a dynamic population model that describes the life
course of cohorts in terms of transitions between risk fac-
tor classes and changes between disease states over time.
Smoking classes distinguished in the CDM are never
smokers, current smokers and former smokers. Body
weight is modeled in three classes using Body Mass Index
(BMI) as indicator: BMI<25 (normal weight), 25 ≤
BMI<30 (overweight), BMI ≥30 (obesity). All model
parameters and variables are specified by gender and age.
The CDM has been formulated as a set of time-continuous
differential equations and the Runge-Kutta method is
used to find initial values and numerical approximations
for 1 year time steps used in the CDM [13]. The main
model outcome variables are incidence, prevalence and
mortality numbers, specified by disease, age and gender.
The CDM has been used in disease projections and cost
effectiveness analyses [14-17].
Using the CDM, we estimated life expectancy (LE) and
HALE for three different cohorts:
- a 'healthy living' cohort: a cohort of never smoking men
and women aged 20 with a normal weight;
- a 'smoking' cohort: a cohort of men and women aged 20
that smoke throughout their life with a normal weight;
- an 'obese' cohort: a cohort of never smoking men and
women aged 20 with a BMI above 30.
The basic formula with which we estimated HALE for the
different cohorts is:
HALE Health-Adjusted Life Expectancy
HSV(t) Health State Valuation of the cohort at time t
HALE
HSV t N t
N
t = ()
∑ () * ()
() 0
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N(t) number of survivors of the cohort at time t
N(0) initial size of the cohort at time 0
Using the CDM we estimated the number of survivors and
the health state valuations corresponding with the time
dependent disease status of the different cohorts. For our
calculations, we did not take into account transitions
between risk factor classes over time. Thus, all cohorts are
closed in the sense that no transitions occur between risk
factor classes over the life-time.
Calculating health state valuations
Health state valuations were calculated by coupling dis-
ease prevalence rates to disability weights available from
the Dutch Burden of Disease study [18]. This specific form
of HALE has also been termed disability-adjusted life
expectancy (DALE) [19,20]. Disability weights reflect the
severity and impact of a disease relative to death and
health without diseases and range from 0 (no disability)
to 1 (death) [21]. Since the construct of disability encom-
passes multiple dimensions that are not necessarily of car-
dinal nature, all valuation methods to scale disability to a
0 to 1 scale imply value choices [21]. The Dutch Burden of
Disease Study estimated disability weights of 48 different
disease categories, using a large panel of experts and the
person trade off method [18] and disease prevalence rates
of these different diseases [7].
To estimate comorbidity prevalence, we assumed inde-
pendence between diseases. Disability weights for comor-
bidity were defined, assuming a multiplicative model
[22], which implies that disability increases with the
number of conditions one has, but that the overall effect
is less than additive:
p(d | t) prevalence rate of disease d at time t
w(d) disability weight for disease d
For diseases causally related to BMI and smoking, we used
the CDM to estimate time dependent disease prevalence
rates (in Appendix A, all diseases related to smoking and/
or obesity that are modeled in the CDM are shown). To
capture the impact on health state valuations of diseases
not causally related to BMI or smoking we used age and
gender specific prevalence rates from the Dutch Burden of
Disease Study for those diseases and assumed them con-
stant over time.
Estimating life years and disease prevalence rates with the 
CDM
For all diseases related to smoking and/or obesity mod-
eled in the CDM, age and sex specific incidence, preva-
lence and mortality rates were estimated using a three
state transition model [23,24]. Formula (3) denotes the
change over time in the prevalence rate of disease d for a
cohort, homogeneous in its risk factor class prevalence, as
a function of relative risks, incidence and mortality rates
(for notational simplicity, age and sex indices have been
omitted in the notation throughout the paper):
 = (i(d)0 * RR(d | sj) * RR(d | bk) 
                    - em(d) * p(d | t))*(1 - p(d | t))   (3)
p(d | t) prevalence rate disease d at time t
i(d)0 baseline incidence rate disease d for 'healthy living' cohort
RR(d | sj) relative risk for disease d for smoking class j
RR(d | bk) relative risk for disease d for BMI class k
em(d) excess mortality rate disease d
Risk factors and diseases are linked through relative risks
of disease incidence for each risk factor. That is, incidence
rates for each risk factor class are found as relative risks
times baseline incidence rate. The general assumption
used is that conditional on the risk factors included, the
disease event rates are independent [25]. For the 'healthy
living cohort' relative risks equal one. Appendix B
describes how the baseline incidence rate for the 'healthy
living' cohort can be derived from incidence rates meas-
ured in the general population using relative risks and risk
factor class prevalence rates. To estimate incidence, preva-
lence and mortality rates in the general population, three
types of data sources were used: general practitioner regis-
trations, national registries, and population surveys
[26,27]. For cancers, national registries were considered
the most reliable source. Data for most non-cancer dis-
eases were based on a combination of up to 5 different
general practitioner registrations or other medical care
registrations. Risk factor prevalence rates for smoking are
based on data of STIVORO [28]. For obesity, data from
the annual POLS survey from Statistics Netherlands are
used [29]. Relative risks on morbidity and mortality for
smoking and obesity are based on several observational
studies [30-53]. Relative risks of the three BMI classes were
calculated in three steps. First, a quadratic function was
estimated to describe the non-linear relation between BMI
and all cause mortality relative risks for different studies.
The parameters of these functions were then plotted
against age to estimate an age gradient. In a third step,
HSV t p d t w d
d
() ( |) () =− ∗ () ( ) ∏ 12
dp d t
dt
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average relative risks for the three different BMI classes
were computed using the BMI distribution within these
classes in the Netherlands. For the current and former
smoking classes distinguished in the CDM, data were used
from studies that reported relative risks for all current and/
or all former smokers specified by gender and age. A sup-
plementary file containing input data used in the CDM for
our calculations is available online [see Additional file 1].
The CDM describes disease prevalence numbers for each
disease separately and it is assumed that the disease-spe-
cific attributed mortality rates are additive. Given the rela-
tions between disease specific attributed mortality, other
causes mortality, disease prevalence rates and relative risks
we can describe the change in population numbers
needed to estimate life expectancy (see Appendix B for a
derivation of the other causes mortality risk):
RR(oc | sj) relative risk for other causes mortality 
                smoking class j
RR(oc | bk) relative risk for other causes mortality BMI class k
m(oc)0 baseline other causes mortality rate for 'healthy living'
cohort
am(d) mortality rate attributed to disease d
The difference of the mortality rates for persons with and
without the disease can be interpreted as the excess mor-
tality rate for that disease. However, in a model with mul-
tiple diseases these excess mortality rates cannot be
interpreted as mortality uniquely attributable to a disease,
since the excess mortality rates can also be caused by other
co-morbid chronic diseases, e.g. coronary heart disease
being a complication of diabetes. Therefore, in the calcu-
lation of the prevalence rates excess mortality rates are
used, while in the calculation of the number of survivors
disease specific attributed mortality rates are used.
Measuring compression or expansion of morbidity
Differences between LE and HALE indicate the life years
that are lost due to ill health and can be interpreted as
'unhealthy' life expectancy or expected years lived with
disability. Thus, the ratio HALE/LE can be interpreted as
the proportion of life expectancy spent in good health.
Absolute compression occurs when 'unhealthy' life
expectancy decreases and absolute expansion occurs when
'unhealthy' life expectancy increases. Relative compres-
sion occurs when the ratio (LE-HALE)/LE decreases and
relative expansion occurs when this ratio increases [6].
Thus, prevention of obesity and smoking results in abso-
lute compression of morbidity if the expected years lived
with disability is lowest for the cohort of healthy living
people. Relative compression due to prevention occurs if
the ratio (LE-HALE)/LE is lowest for healthy living people.
Sensitivity analyses
In our baseline estimates of LE and HALE it is assumed
that relative risks, incidence rates and mortality rates are
constant over time. However, in the past, due to medical
progress mortality rates of cardiovascular diseases have
been declining [54,55]. In a similar fashion, it has been
argued that the excess risk of obesity on cardiovascular
disease has decreased over time due to better treatment of
other risk factors or intermediates like hypertension and
diabetes [56,57]. Another crucial factor in HALE calcula-
tions and conclusions about compression or expansion of
morbidity are the health state valuations of the different
cohorts. Since the extra life years gained by successful pre-
vention are lived at high ages the extent to which the
health state valuations of the cohorts decrease with age
strongly influences conclusions on compression or expan-
sion of morbidity.
To investigate the robustness of our results with respect to
future changes in disease epidemiology and the age gradi-
ent of the health state valuations we have carried out a
series of sensitivity analyses by estimating LE and HALE
for the three cohorts in the following scenarios:
- scenario 1: a yearly decrease of 1% in attributable mortal-
ity rates for all diseases included in the model;
- scenario 2: a yearly decrease of 1% in disease incidence
rates for all diseases included in the model;
- scenario 3: a yearly decrease of 1% in both disease inci-
dence and attributable mortality rates for all diseases
included in the model;
- scenario 4: a yearly decrease in all relative risks of the
obese and smoking cohort using the following formula:
RRt = (RRt-1-1)*0.99 + 1 where RRt is the relative risk in
year t;
- scenario 5: health state valuations for all cohorts at all
ages were recalculated by subtracting 30% of mean age
and sex specific total disability (defined as 1 minus the
health state valuation) as estimated using the Dutch Bur-
den of Disease data [22]. This implies a sharper decrease
in the health status of the cohorts at older ages. At ages 80
and over this means a reduction larger than 0.1 in the
health state valuations of all cohorts.
In scenario 1, 2 and 3 the decrease in mortality and/or
incidence rates roughly equals the decrease as used in the
dN t
dt
RR oc s RR oc b m oc N t am d p d t N t jk
d
()
( | )* ( | )* ( ) * ( ) ( )* ( | )* ( ) =− 0 ∑ ∑ () 4Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
Page 5 of 13
(page number not for citation purposes)
Global Burden of Disease projections of global mortality
and burden of disease [58]. Scenario 4 reflects the effects
of selective disease prevention efforts in smokers and
obese as has been observed in the past [56,57]. In scenario
5 we account for the incomplete nature of the Dutch bur-
den of disease: compared to the Global Burden of Disease
2000 study, the diseases selected in the Dutch Burden of
Disease study [7] account for only 70% of years lived with
disability for European region A [59].
Results
Figures 1 and 2 display survival curves for the different
cohorts for men and women. From the survival curves, it
appears that smokers have the lowest life expectancy and
that 'healthy living' people have the highest life expect-
ancy.
For the survivors at different points in time, the disease
prevalence rates coupled to disability weights can be used
to estimate average health state valuations for the different
cohorts. Figure 3 and 4 display these average health state
valuations for men and women.
At low ages, health state valuations for all cohorts are sim-
ilar, but for higher ages health state valuations are lowest
for smokers, with differences between smokers and
healthy living people increasing up to 0.12. For men, the
differences in health state valuations between smokers
and obese people are larger than for women. These results
suggest that obesity causes relatively more disability in
women and smoking more disability in men.
Combining these health state valuations with the life
years as displayed in Figures 1 and 2 leads to estimates of
HALE as shown in Tables 1 and 2.
At age 20 there is a difference in 7.7 years in LE for smok-
ing men compared to healthy men and a difference in LE
of 4.7 years for obese men compared to healthy living
men. Differences in HALE compared to healthy living
men at age 20 are 7.8 years and 4.6 years, for smoking and
obese men respectively. At older ages differences in HALE
are larger than differences in LE.
Compared to men, decreases in LE and HALE due to
smoking and obesity as compared to healthy living are
smaller for women. At age 20 there is a difference of 6.3
years in LE for smoking women compared to healthy liv-
ing women and a difference in LE of 4.4 years for obese
women compared to healthy living women. Compared to
healthy living women, differences in HALE at age 20 are
6.0 and 4.5 for smoking and obese women, respectively.
Now that LE and HALE have been estimated for the differ-
ent cohorts, we will address the following question: does
prevention of smoking and obesity at young age result in
absolute and/or relative compression of morbidity? Table
3 shows that absolute compression occurs due to smoking
prevention for men and obesity prevention in women.
Absolute expansion occurs for smoking prevention in
women and obesity prevention in women. However, suc-
cessful prevention will always result in relative compres-
sion, implying that the period lived with morbidity
decreases relative to total life expectancy when prevention
policies will be successful.
Survival curves for men of the different cohorts Figure 1
Survival curves for men of the different cohorts.Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
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Table 4 displays the results of the sensitivity analysis.
Future increases in disease mortality and/or incidence
rates increase LE and HALE estimates for all cohorts for
both men and women (scenarios 1, 2 and 3). As expected,
decreasing relative risks over time results in smaller differ-
ences in LE and HALE between the cohorts (scenario 4).
Addition of GBD data and a sharper decrease in the health
state valuations of all cohorts at older ages lowers HALE
estimates substantially (scenario 5). However, differences
in HALE between the different cohorts remain substantial
in all scenarios: compared to the 'healthy living' cohort
HALE estimates of the smoking cohort are minimally 6.3
years lower for men and 4.9 years lower for women. For
the obese cohort the minimum differences are 4.0 years
and 3.8 years for respectively men and women. In most
scenarios 'unhealthy' life expectancies are highest for the
'healthy living' cohort indicating an absolute expansion of
morbidity if smoking and/or obesity is prevented. This
effect is most pronounced in scenario 5. However, in none
Health State Valuations (HSV) for survivors of different cohorts (men) Figure 3
Health State Valuations (HSV) for survivors of different cohorts (men).
Survival curves for women of the different cohorts Figure 2
Survival curves for women of the different cohorts.Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
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of the scenarios does prevention result in relative expan-
sion of morbidity.
Discussion and conclusion
In this paper, estimates of HALE were presented for differ-
ent cohorts defined conditional on risk factor classes. Esti-
mates of HALE are highest for 'healthy living' people (54.8
for men and 55.4 for women at age 20). Differences in
HALE compared to 'healthy living' men at age 20 are 7.8
and 4.6 for respectively smoking and obese men. Differ-
ences in HALE compared to 'healthy' women at age 20 are
6.0 and 4.5 for respectively smoking and obese women. At
older ages differences in HALE are larger than differences
in LE. For all cohorts unhealthy life expectancies are
approximately 8 years for men and 10 years for women.
As a result, a slight relative compression of morbidity
occurs if prevention of smoking and/or obesity is success-
ful. Estimates of LE and HALE and conclusions about
compression of morbidity should be made with great cau-
tion because of uncertainty with respect to future changes
in disease epidemiology. In sensitivity analyses we inves-
tigated the sensitivity of our results to future changes in
disease epidemiology and to changes in the age gradient
of the health state valuations of the different cohorts.
Main results of the sensitivity analyses were that although
estimates of LE and HALE are sensitive to changes in dis-
Table 2: Life Expectancy (LE) and Health Adjusted Life 
Expectancy (HALE) for women (between brackets: difference 
with 'healthy living' cohort)
AGE LE HALE 'Healthy living' 
cohort
Smoking 
cohort
Obese 
cohort
20 LE 65.7 59.4 61.3
(-6.3) (-4.4)
HALE 55.4 49.4 50.8
(-6.0) (-4.5)
40 LE 47.0 40.8 42.8
(-6.2) (-4.2)
HALE 37.5 31.6 33.1
(-5.9) (-4.4)
65 LE 23.2 18.2 20.1
(-5.0) (-3.1)
HALE 18.0 12.2 14.0
(-5.8) (-4.0)
Health State Valuations (HSV) for survivors of different cohorts (women) Figure 4
Health State Valuations (HSV) for survivors of different cohorts (women).
Table 1: Life Expectancy (LE) and Health Adjusted Life 
Expectancy (HALE) for men (between brackets: difference with 
'healthy living' cohort)
AGE LE HALE 'Healthy living' 
cohort
Smoking 
cohort
Obese 
cohort
20 LE 63.1 55.4 58.5
(-7.7) (-4.7)
HALE 54.8 46.9 50.2
(-7.8) (-4.6)
40 LE 44.6 37.1 40.1
(-7.5) (-4.5)
HALE 37.0 29.2 32.5
(-7.8) (-4.5)
65 LE 21.0 15.4 17.8
(-5.6) (-3.2)
HALE 16.5 9.4 12.5
(-7.1) (-4.0)Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
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ease epidemiology, differences in LE and HALE between
the different cohorts remain substantial. Furthermore,
although a sharper decrease in the health state valuations
at older ages results in an absolute expansion of morbidity
this does not result in a relative expansion of morbidity.
Overall, in most scenarios the proportion of life expect-
ancy spent in good health is a fairly stable proportion for
the different cohorts.
It is argued that an incidence based estimate of HALE
using a state-transition model is a better indicator than a
prevalence based indicator for public health policy since
it is not biased by the stock of diseases built up in the past
[60]. The drawback of an incidence based methodology is
that state-transition models are required for which the
data requirements are very large. To minimize data
requirements, we only modeled marginal disease preva-
lence rates, and did not model comorbidity (joint disease
prevalence rates). However, as with any modeling study,
results depend on the assumptions used in constructing
the simulation model and the input data used. We will
first discuss the different assumptions and then proceed to
discuss the sensitivity of the results in relationship to the
input data used.
Table 4: Results of sensitivity analysis: LE, HALE, LE-HALE and (LE-HALE)/LE for men and women at age 20 (between brackets: 
difference with 'healthy living' cohort)
MEN WOMEN
'Healthy living' cohort Smoking cohort Obese cohort 'Healthy living' cohort Smoking cohort Obese cohort
Scenario 1 LE 66.4 58.8
(-7.6)
61.2
(-4.2)
68.9 62.1
(-6.7)
64.2
(-4.7)
HALE 57.0 49.2
(-6.8)
52.0
(-5.0)
57.4 51.2
(-6.2)
52.7
(-4.7)
LE-HALE 9.4 9.6 9.2 11.4 10.9 11.5
(LE-HALE)/LE 0.14 0.16 0.15 0.17 0.18 0.18
Scenario 2 LE 68.0 60.0
(-8.0)
62.5
(-5.5)
69.9 62.9
(-7.0)
65.1
(-4.8)
HALE 59.8 52.3
(-7.5)
54.8
(-5.0)
59.7 53.6
(-6.1)
55.3
(-4.4)
LE-HALE 8.1 7.8 7.7 10.2 9.2 9.8
(LE-HALE)/LE 0.12 0.13 0.12 0.15 0.15 0.15
Scenario 3 LE 69.9 62.2
(-7.7)
64.2
(-5.7)
71.5 64.3
(-7.2)
66.7
(-4.8)
HALE 61.3 53.9
(-7.4)
56.1
(-5.2)
60.9 54.8
(-6.1)
56.5
(-4.4)
LE-HALE 8.6 8.3 8.0 10.6 9.6 10.3
(LE-HALE)/LE 0.12 0.13 0.12 0.15 0.15 0.15
Scenario 4 LE 63.1 56.8
(-6.3)
58.9
(-4.2)
65.7 60.3
(-5.4)
61.8
(-3.9)
HALE 54.8 48.5
(-6.3)
50.8
(-4.0)
55.4 50.5
(-4.9)
51.6
(-3.8)
LE-HALE 8.4 8.3 8.1 10.3 9.8 10.3
(LE-HALE)/LE 0.13 0.15 0.14 0.16 0.16 0.17
Scenario 5 LE 63.1 55.4
(-7.7).
58.5
(-4.7)
65.7 59.4
(-6.4)
61.3
(-4.4)
HALE 51.6 44.5
(-7.1)
47.5
(-4.1)
52.1 46.7
(-5.4)
48.0
(-4.1)
LE-HALE 11.5 10.9 11.0 13.6 12.7 13.3
(LE-HALE)/LE 0.18 0.20 0.19 0.21 0.21 0.22
Table 3: Unhealthy life expectancy (LE-HALE) and unhealthy life expectancy relative to life expectancy (LE-HALE)/LE at age 20
'Healthy living' cohort Smoking cohort Obese cohort
Men LE-HALE 8.4 8.5 8.3
(LE-HALE)/LE 0.13 0.15 0.14
Women LE-HALE 10.3 10.0 10.5
(LE-HALE)/LE 0.16 0.17 0.17Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
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First of all, we did not distinguish between light and heavy
smokers, and BMI was not treated as a continuous varia-
ble. The relative risks used for the BMI classes are risk fac-
tor class averages calculated using data on the BMI
distribution in the Netherlands. Using risk factor class
averages in a cohort implies, over age, the most obese tend
to die early reducing the mean level of obesity, with age.
To what extent the risk factor class averages calculated
using the current BMI distributions in the Netherlands can
be used as an approximation to simulate average relative
risks of a cohort depends on the stability of these distribu-
tions over time.
To estimate baseline incidence and mortality rates for the
'healthy living' cohort, we assumed independence
between risk factor classes and multiplicative relative
risks. Furthermore, relative risks on disease incidence rates
are used as an approximation for disease prevalence rates
to estimate relative risk for the different cohorts on other
causes of death. Although these assumptions may be vio-
lated in practice, necessary data to fill this gap are missing.
Another crucial assumption was the one regarding excess
mortality risks. Patients with a specific disease have a
higher mortality risk than persons without the disease, all
other variables equal. The difference in mortality is
expressed here as excess mortality which is used in calcu-
lations of the disease prevalence rates. However, in gen-
eral only part of this excess mortality can be attributed to
the specific disease, which is used in our calculations of
population numbers. The difference between the excess
mortality and the part uniquely attributable to the disease
can be interpreted as mortality due to co-morbid condi-
tions. The mortality due to co-morbid conditions is espe-
cially important on higher ages, such as for COPD for
which smoking is an important risk factor with many
other related chronic diseases. So part of the COPD excess
mortality must be attributed to other smoking related dis-
eases (e.g. coronary heart disease and lung cancer) [61].
Therefore, in the calculation of the prevalence rates excess
mortality rates are used, while in the calculation of the
number of survivors disease specific attributed mortality
rates are used. So far, the problem of excess mortality has
received relatively little attention in most population
models. Therefore, developing methods to establish rela-
tions between excess mortality rates and attributable mor-
tality rates should deserve more attention.
Disability weights for comorbidity were defined assuming
a multiplicative adjustment method. We tested for this
using alternative weighing methods [22]. Although this
affected absolute estimates of HALE it only had a minor
influence on differences in HALE. The same also goes for
the influence of diseases not causally related to BMI and/
or smoking. Excluding them raised HALE estimates, but
did not affect substantially the differences found between
groups.
Lastly, we assumed that no transitions occur between risk
factor classes over time. In reality, of course, transitions
between classes do occur: some smokers quit (and some
of them might start again later) and obese people of
course might lose weight. Moreover, obesity has a more
complex age trajectory than smoking in that body compo-
sition changes with age [62].
Recently, it was argued that the excess mortality due to
obesity had been overestimated and that the effects of
obesity attenuate with age, and are not strongly related to
mortality above age 70 to 75 [63,64]. Of course, our esti-
mates of LE, and thus also of HALE, would increase for the
obese cohort if we imputed relative risks as reported by a
study finding lower risks. Other studies, however,
reported higher mortality risks associated with obesity
[39] which would lead to lower LE estimates for the obese
cohort [65]. Moreover, in our analysis, our cohort was
defined as being obese but non-smoking. It has been
shown that excess mortality due to obesity is highest for
never smokers [39,65].
Even though successful prevention would result in health
gains this is not necessarily accompanied by a reduction in
health care costs. A decline in costs due to risk factor
related diseases may well be outweighed by an increase in
costs due to risk factor unrelated diseases, especially in life
years gained. Prevention, when successful in prolonging
life, may therefore cause more costs than it avoids [66,67].
However, this will of course largely depend on the risk fac-
tor under study. A next step, therefore, would be to com-
pare the effects of smoking and obesity prevention on
health care costs. We conclude that losses in HALE due to
smoking and obesity are substantial and that prevention
of smoking and obesity can considerably increase both
life expectancy and health-adjusted life expectancy. This
knowledge underpins the importance of continuing pub-
lic health policies to prevent unhealthy behavior. How-
ever, our results do not indicate that substantial
compression of morbidity is to be expected as a result of
successful smoking or obesity prevention.
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Appendix A: Diseases related to smoking and 
obesity in the CDM
Appendix B: Calculating baseline mortality and 
incidence rates with the CDM
Calculating baseline mortality rates and risk factor class 
specific mortality rates
Mortality rates from Statistics Netherlands for the year
2004 [29] are attributed to risk factor classes to derive
mortality rates specified by risk factor class. Assuming
independence between risk factor class prevalence rates
and multiplicative relative risks (i.e. no interaction on log-
linear scale) we can write mortality rates for the different
cohorts as:
m(tot | si, bj) = m(tot)0 * RR(tot | sj) * RR(tot | bk)   (B1.1)
m(tot | si, bj) all cause mortality rate for cohort for smoking
class j BMI class k
m(tot)0 baseline all cause mortality rate for 'healthy living'
cohort
RR(tot | sj) relative risk all cause mortality smoking class j
RR(tot | bk) relative risk all cause mortality BMI class k
Using (B1.1) we can write the baseline mortality rate for
the 'healthy living' cohort as:
m(tot) all cause mortality rate (Statistics Netherlands)
sj prevalence rate smoking class j
bj prevalence rate BMI class k
Calculating baseline disease incidence rates and risk factor 
class specific disease incidence rates
i(d | sj, bk) = i(d)0 * RR(d | sj) * RR(d | bk)   (B2.1)
i(d | si, bj) incidence rate disease d for cohort smoking class j
BMI class k
i(d)0 baseline incidence rate for 'healthy' cohort
RR(d | sj) relative risk for disease d smoking class j
RR(d | bk) relative risk for disease d BMI class k
i(d) population incidence rate disease d
Calculating baseline risk factor class specific relative risk 
for other causes mortality
The CDM describes disease prevalence numbers for each
disease separately and it is assumed that the disease-spe-
cific attributed mortality rates are additive. The all cause
mortality rates are the sum of the disease specific attrib-
uted mortality rates and the mortality rates from other
causes of death:
m(oc) mortality rate for other causes of death
p(d) disease d prevalence rates (several sources)
am(d) mortality rate attributed to disease d
Mortality rates attributed to diseases are calculated by
dividing the cause specific mortality rates registered by
Statistics Netherlands by disease specific prevalence rates:
mt o t
mt o t
RR tot s RR tot b s b jk
jk
jk
()
()
(| ) *(|) **
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,
0 12 = ()
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id
id
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Table A1: diseases modeled in the CDM and their relation to 
smoking and obesity
Related to smoking Related to obesity
Cardiovascular disease
Acute myocardial infarct (AMI) ++
Angina pectoris ++
Chronic Heart Failure ++
Stroke (CVA) ++
Cancer
Lung +
Stomach +
Oesophagus +
Pancreas +
Oral cavity +
Larynx +
Uriny bladder +
Kidney ++
Rectum +
Colon +
Breast +
Prostate +
Endometrium +
Other
COPD +
Diabetes ++
Atrhrosis of the hip +
Arthrosis of the knee +
Dorsopathies (low back pain) +Population Health Metrics 2006, 4:14 http://www.pophealthmetrics.com/content/4/1/14
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c(d) cause specific mortality rate disease d
It is assumed that for any disease the attributed mortality
is independent from the risk factor levels. This means that
the risk factors affect the disease prognosis only through
increased risks for other diseases and mortality from other
causes of death. Using the relative risk for the incidence of
diseases as an approximation for relative risk for the prev-
alence of diseases we calculated the relative risks for other
causes of death:
RR(oc | sj) relative risk for other cause mortality smoking class j
m(oc)0s baseline other cause mortality rate for non smoking
cohort
p(d)0s baseline prevalence rate disease d for non smoking cohort
m(tot)0s baseline all cause mortality rate for non smoking
cohort
These equations can be solved for RR(oc | sj,) by substitut-
ing equations (B3.4) and (B3.5) into equation (B3.3). In
a similar fashion, relative risks for other causes mortality
of for overweight and obesity can be derived. Given RR(oc
| sj,) and RR(oc | bk,) the baseline other cause mortality rate
can be found:
RR(oc | sj, bk) = RR(oc | sj) * RR(oc | bk)   (B3.6)
RR(oc | sj, bk) relative risk for other cause mortality smoking
class j BMI class k
RR(oc | bk) relative risk for other cause mortality BMI class k
m(oc)0 baseline other cause mortality rate for 'healthy living'
cohort
p(d)0 baseline prevalence rate disease d for 'healthy living'
cohort
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